1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc.

CRDL.TO
Cardiol Therapeutics Inc.CA flagToronto Stock Exchange
1.44
CAD
-0.09
- -
165.42MMarket Cap
Cardiol Therapeutics Inc.
CRDL.TO
(Toronto Stock Exchange)

Recent

price

1.44

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.07
-1.03
-0.53
-0.69
-0.73
-0.49
-0.44
-0.51
-0.39
-0.39
Basic EPS, GAAP
-0.06
-0.71
-0.46
-0.31
-0.54
-0.44
-0.39
-0.35
-0.27
-0.26
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.11
1.25
0.32
- -
1.37
0.53
0.09
- -
-0.13
-0.12
Book Value per Share
0.09
1.41
0.55
0.43
1.76
0.83
0.43
0.35
0.21
0.26
Tangible Book Value per Share
23
15
26
30
43
63
64
72
87
92
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
-49,091.93
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-2
-16
-14
-21
-32
-31
-28
-37
-34
-36
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
-40,170.45
- -
- -
- -
- -
- -
Profit Margin (%)
2
22
14
12
76
52
28
25
18
24
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
3
22
15
13
76
52
28
25
18
24
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-146.07
-100.09
-502.29
-106.45
-66.88
-144.1
-1,217.78
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
87
100
112
Market Capitalization
126
109
174

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
13
24
31
Cash, Cash Equivalents & STI
12
21
28
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
6
7
Payables & Accruals
3
3
3
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
71.39%
-27.7%
Free Cash Flow
- -
31.96%
-4.8%
Net Income, GAAP
- -
12.92%
-7.79%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.14
-0.1
-0.18
- -
-0.51
2025
-0.1
-0.1
-0.12
- -
-0.39
2026
-0.1
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Hero Technologies Inc. (HENC)
Ovation Science Inc. (OVATF)
The Valens Company Inc. (VLNS)
Eton Pharmaceuticals, Inc. (ETON)
Alkem Laboratories Limited (ALKEM.NS)
cbdMD, Inc. (YCBD)
Business
Cardiol Therapeutics Inc. is a clinical-stage biopharmaceutical firm dedicated to the research and development of anti-inflammatory and anti-fibrotic treatments for heart conditions. Their primary therapeutic candidate, CardiolRx™, an oral cannabidiol formulation, is progressing through clinical trials. It is currently in a Phase III multi-national, randomized, double-blind, placebo-controlled study (MAVERIC) to evaluate its effectiveness in preventing recurrent pericarditis, a debilitating inflammatory heart disease. Additionally, CardiolRx™ is undergoing a Phase II multi-national, randomized, double-blind, placebo-controlled trial (ARCHER) to assess its impact on myocardial recovery in patients with acute myocarditis, a serious condition affecting the heart muscle. The company is also developing CRD-38, a novel subcutaneously administered cannabidiol formulation, which is in preclinical stages for the treatment of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.

Company News

APIChatGPT

  • defenseworld.net

    Cardiol Therapeutics (TSE:CRDL) Shares Down 7.1% – Time to Sell?

  • defenseworld.net

    Cardiol Therapeutics (TSE:CRDL) Shares Down 7.1% – What’s Next?

  • defenseworld.net

    Cardiol Therapeutics (TSE:CRDL) Trading Down 3.5% – What’s Next?